Agenus Net Profit Margin 2010-2022 | AGEN

Agenus net profit margin from 2010 to 2022. Net profit margin can be defined as net Income as a portion of total sales revenue.
Agenus Net Profit Margin Historical Data
Date TTM Revenue TTM Net Income Net Margin
2022-03-31 $0.31B $-0.02B -6.13%
2021-12-31 $0.30B $-0.03B -8.45%
2021-09-30 $0.31B $0.00B 0.98%
2021-06-30 $0.07B $-0.23B -327.54%
2021-03-31 $0.09B $-0.19B -224.71%
2020-12-31 $0.09B $-0.18B -206.82%
2020-09-30 $0.09B $-0.17B -189.13%
2020-06-30 $0.10B $-0.17B -174.23%
2020-03-31 $0.09B $-0.17B -200.00%
2019-12-31 $0.15B $-0.11B -72.19%
2019-09-30 $0.12B $-0.13B -104.10%
2019-06-30 $0.12B $-0.11B -99.13%
2019-03-31 $0.12B $-0.09B -76.52%
2018-12-31 $0.04B $-0.16B -432.43%
2018-09-30 $0.04B $-0.15B -376.92%
2018-06-30 $0.03B $-0.15B -520.69%
2018-03-31 $0.02B $-0.16B -929.41%
2017-12-31 $0.04B $-0.12B -288.10%
2017-09-30 $0.04B $-0.11B -280.00%
2017-06-30 $0.04B $-0.12B -282.93%
2017-03-31 $0.04B $-0.11B -254.55%
2016-12-31 $0.02B $-0.13B -552.17%
2016-09-30 $0.03B $-0.12B -468.00%
2016-06-30 $0.03B $-0.09B -317.86%
2016-03-31 $0.03B $-0.10B -374.07%
2015-12-31 $0.03B $-0.09B -352.00%
2015-09-30 $0.02B $-0.10B -515.79%
2015-06-30 $0.01B $-0.09B -664.29%
2015-03-31 $0.01B $-0.06B -554.55%
2014-12-31 $0.01B $-0.04B -525.00%
2014-09-30 $0.01B $-0.02B -366.67%
2014-06-30 $0.01B $-0.02B -420.00%
2014-03-31 $0.00B $-0.02B -800.00%
2013-12-31 $0.00B $-0.03B -1100.00%
2013-09-30 $0.00B $-0.03B -825.00%
2013-06-30 $0.00B $-0.03B -800.00%
2013-03-31 $0.00B $-0.03B -700.00%
2012-12-31 $0.02B $-0.01B -75.00%
2012-09-30 $0.02B $-0.01B -75.00%
2012-06-30 $0.02B $-0.01B -75.00%
2012-03-31 $0.02B $-0.01B -68.75%
2011-12-31 $0.00B $-0.02B -600.00%
2011-09-30 $0.00B $-0.02B -525.00%
2011-06-30 $0.00B $-0.02B -525.00%
2011-03-31 $0.00B $-0.02B -500.00%
2010-12-31 $0.00B $-0.02B -575.00%
2010-09-30 $0.00B $-0.02B -450.00%
2010-06-30 $0.00B $-0.02B -575.00%
2010-03-31 $0.00B $-0.03B -750.00%
2009-12-31 $0.00B $-0.03B -775.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.554B $0.296B
Agenus Inc., formerly known as Antigenics Inc., is engaged in the discovery, development and commercialization of immunotherapeutics for the treatment of life threatening and chronic medical conditions. Immunotherapeutics are drugs that work by modulating the immune system to fight diseases. The Company's product line includes Oncophage vaccine, a patient-specific therapeutic cancer vaccine. The Company is also developing Prophage, patient-specific therapeutic cancer vaccine; QS-21, vaccine adjuvant; and HerpV, a polyvalent off-the-shelf therapeutic heat shock protein-based vaccine for treatment of genital herpes which are all in the clinical testing stages. Agenus Inc. is headquartered in Lexington, Massachusetts.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.597B 9.95
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
QIAGEN (QGEN) Netherlands $10.865B 17.15
Biohaven Pharmaceutical Holding (BHVN) United States $10.248B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Emergent Biosolutions (EBS) United States $1.599B 6.85
Myovant Sciences (MYOV) United Kingdom $1.236B 0.00
Zymeworks (ZYME) Canada $0.320B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.087B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00